Company Monitoring Page for Eisai

latest headlines for company on cafepharma

The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
Medical Marketing and Media
Wed, 08/2/23 - 10:43 pm
Tags:
Eisai, Biogen, Leqembi, Alzheimer's disease
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Fierce Pharma
Thu, 07/20/23 - 10:09 am
Tags:
Eisai, Biogen, Leqembi, FDA, Alzheimer's disease, subcutaneous drug delivery
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Tags:
Eli Lilly, donanemab, Eisai, Biogen, Leqembi, Alzheimer's disease
Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen
BioSpace
Tue, 07/18/23 - 11:36 am
Tags:
CMS, Alzheimer's disease, Eisai, Biogen, PET scans
Why new Alzheimer’s drugs are in for a tepid launch
Medical Marketing and Media
Sun, 07/16/23 - 03:11 pm
Tags:
Alzheimer's disease, drug launches, Biogen, Eisai, Leqembi
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Motley Fool
Thu, 07/13/23 - 10:16 am
Tags:
Biogen, Eisai, Leqembi, Alzheimer's disease
How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know
Fierce Pharma
Wed, 07/12/23 - 11:03 pm
Tags:
Eisai, Biogen, Leqembi, drug pricing, Medicare, Alzheimer's disease
Eisai's US CEO and Alzheimer's lead Ivan Cheung telegraphs retirement days after Leqembi's full FDA nod
Fierce Pharma
Tue, 07/11/23 - 11:20 pm
Tags:
Eisai, Alzheimer's disease, Leqembi, Ivan Cheung
Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s
BioSpace
Thu, 07/6/23 - 10:08 pm
Tags:
Biogen, Eisai, Leqembi, FDA, Alzheimer's disease
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
Tags:
FDA, Eisai, Biogen, Leqembi, Alzheimer's disease, SAGE Therapeutics, zuranolone, postpartum depression, major depressive disorder, Roche, Tecentriq, non-small cell lung cancer, CRISPR Therapeutics, Bluebird Bio, lovo-cel, exa-cel, BrainStorm Cell Therapeutics, NurOwn
5 FDA decisions to watch in the third quarter
BioPharma Dive
Mon, 06/26/23 - 10:04 am
Tags:
FDA, SAGE Therapeutics, Biogen, zuranolone, Eisai, Leqembi, Sanofi, AstraZeneca, nirsevimab, Iveric Bio, Zimura, Alnylam, Onpattro
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
Motley Fool
Fri, 06/23/23 - 10:03 am
Tags:
Biogen, Eisai, Alzheimer's disease, FDA, Leqembi
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Motley Fool
Mon, 06/19/23 - 10:21 am
Tags:
Eisai, Biogen, Leqembi, Alzheimer's disease, Europe
On the Cusp of Full Approval, Leqembi’s Rollout Could Face Challenges
BioSpace
Fri, 06/16/23 - 10:01 am
Tags:
Eisai, Biogen, Alzheimer's disease, FDA, Leqembi
The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules
Forbes
Wed, 06/14/23 - 06:42 pm
Tags:
Alzheimer's disease, drug pricing, Medicare, Biogen, Eisai, Leqembi
Biopharma Confronts a Rising Tide of Ransomware Attacks
BioSpace
Wed, 06/14/23 - 10:11 am
Tags:
cyberattacks, cybersecurity, ransomware, Eisai, Sun Pharma, Novartis, AstraZeneca, Merck
Eisai goes after head and neck cancer in Made of More campaign
Medical Marketing and Media
Mon, 06/12/23 - 11:24 pm
Tags:
Eisai, head and neck cancer, pharma marketing
FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug
BioPharma Dive
Sun, 06/11/23 - 11:14 pm
Tags:
Eisai, Biogen, Leqembi, FDA, Alzheimer's disease
Pharmaceutical Giant Eisai Hit By Ransomware Incident
Infosecurity Magazine
Sun, 06/11/23 - 11:09 pm
Tags:
Eisai, cyberattack, ransomware
Eisai files Leqembi in Korea, as US prospects firm up
Pharmaphorum
Thu, 06/8/23 - 10:02 am
Tags:
Eisai, Biogen, Leqembi, Alzheimer's disease, South Korea, Asia

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.